Prescription Strategies of Amikacin in Intensive Care Patients on Renal Replacement Therapy: an Observational Prospective Multicenter Study
- Conditions
- Amikacin Treatment
- Interventions
- Other: Data record
- Registration Number
- NCT04322019
- Lead Sponsor
- CHU de Reims
- Brief Summary
Amikacin is the aminoglycoside of choice for treatment of severe infections in intensive care. An achievement of its objectives in pharmacokinetics and pharmacodynamics is difficult in intensive care patients because of modification of their volume of distribution and renal clearance. Acute renal failure requiring renal replacement therapy is frequent in intensive care. Extrarenal purification modalities (continuous versus intermittent, type of dialysis membrane), which can influence amikacin clearance, are multiple and teams dependent. Guidelines of good practice for Amikacin in intensive care patients do not exist.
- Detailed Description
The aim of this study is to describe strategies of prescription and monitoring of Amikacin in intensive care patients on renal replacement therapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 112
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description "Amikacin treatment" group Data record Intensive care patients on renal replacement therapy with Amikacin treatment
- Primary Outcome Measures
Name Time Method Measurement of maximum concentration observed Day 0 Monitoring of Amikacin treatment using measurement of maximum concentration observed performed or not
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Damien JOLLY
🇫🇷Reims, France